When did Lexaria Bioscience report Q2 2025 earnings?

Lexaria Bioscience (LEXX) reported Q2 2025 earnings on July 14, 2025 before market open.

What were Lexaria Bioscience's Q2 2025 revenue and EPS?

Lexaria Bioscience reported revenue of $174.0K and diluted EPS of $-0.21 for Q2 2025.

Revenue beat the consensus estimate of $137.0K by $37.0K. EPS missed the consensus estimate of $-0.15 by $0.06.

Compared to the same quarter a year prior, revenue grew 107.1% from $84.0K a year earlier and diluted EPS declined 61.5% from $-0.13.

You can read the 10-Q periodic report (0001640334-25-001195) directly on SEC EDGAR. The filing index links above go to sec.gov.

Reported July 14, 2025 · Before market open

Revenue estimate$137.0K

EPS estimate-$0.15

Jul 13, 2026 (In 3 weeks)

Revenue estimate$50.0K

EPS estimate-$0.06

Q2 2025$174.0KBeat by $37.0K

Q2 2025-$0.21Miss by $0.06

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

When did Lexaria Bioscience report Q2 2025 earnings?: Lexaria Bioscience (LEXX) reported Q2 2025 earnings on July 14, 2025 before market open.
What were Lexaria Bioscience's Q2 2025 revenue and EPS?: Lexaria Bioscience reported revenue of $174.0K and diluted EPS of $-0.21 for Q2 2025.
Did Lexaria Bioscience beat estimates in Q2 2025?: Revenue beat the consensus estimate of $137.0K by $37.0K. EPS missed the consensus estimate of $-0.15 by $0.06.
How did Lexaria Bioscience's Q2 2025 results compare year-over-year?: Compared to the same quarter a year prior, revenue grew 107.1% from $84.0K a year earlier and diluted EPS declined 61.5% from $-0.13.
Where can I find Lexaria Bioscience's Q2 2025 SEC filings?: You can read the 10-Q periodic report (0001640334-25-001195) directly on SEC EDGAR. The filing index links above go to sec.gov.